Aankondiging • 20h
Restart Life Sciences Corp. announced that it has received CAD 0.1 million in funding On May 21, 2026, Restart Life Sciences Corp. closed the transaction. No finders' fees were paid in connection with the closing of this offering. All securities issued pursuant to the offering are subject to a statutory four-month-and-one-day hold period expiring September 21, 2026, under applicable Canadian securities laws. The company has issued total of 833,334 units at a price of 12 cents per unit for aggregate gross proceeds of CAD 100,000.08. Steve Loutskou has subscribed for 50% of the offering (416,666 units). Aankondiging • May 10
Restart Life Sciences Corp. announced that it expects to receive CAD 0.1 million in funding Restart Life Sciences Corp. announces a non brokered private placement to issue 833,333 units at a price of CAD 0.12 per unit for gross proceeds of up to CAD 99,999.96 on May 8, 2026. Each unit will consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to purchase one additional common share for a period of two years at a price of CAD 0.15 per common share. Finders' fees may be payable in accordance with the policies of the Canadian Securities Exchange (the CSE). All securities issued pursuant to the offering will be subject to a statutory hold period of four months and one day from the date of issuance. Aankondiging • Dec 24
Restart Life Sciences Corp. (CNSX:HEAL) signed a binding letter of intent to acquire Holy Crap Foods Inc. from Happy Belly Food Group Inc. (CNSX:HBFG) for CAD 1 million. Restart Life Sciences Corp. (CNSX:HEAL) signed a binding letter of intent to acquire Holy Crap Foods Inc. from Happy Belly Food Group Inc. (CNSX:HBFG) for CAD 1 million on December 21, 2025. Purchase price is subject to working capital adjustments. Restart will pay Happy Belly Food Group Inc. a cash deposit of CAD 0.1 million being equal to 10% of the purchase price.
For the period ending December 31, 2024, Holy Crap Foods Inc. reported annual sales of CAD 1 million.
The transaction is subject to approval by the Canadian Securities Exchange and is expected to close in early 2026. Aankondiging • Nov 13
Restart Life Sciences Corp. announced that it expects to receive CAD 1 million in funding Restart Life Sciences Corp. announced non-brokered private placement of up 10,000,000 units at a price of CAD 0.10 per unit for gross proceeds of CAD 1,000,000 on November 12, 2025. Each Unit purchased will include one common share and one transferable common share purchase warrant . Each Warrant will entitle the holder to purchase one additional common share for a period of one year at a price of CAD 0.10 per common share. Finders' fees may be payable in accordance with the policies of the Canadian Securities Exchange. All securities issued pursuant to the offering will be subject to a hold period of four months and one day from the date of issuance. Aankondiging • Jul 09
Restart Life Sciences Corp. announced that it expects to receive CAD 1 million in funding Restart Life Sciences Corp. announces a non-brokered private placement to issue 10,000,000 common shares at a price of CAD 0.10 for gross proceeds of CAD 1,000,000 on July 8, 2025. The Offering is expected to close on or before August 21, 2025.The Company may pay a finders fees in cash equal to 8.0% of the aggregate gross proceeds of the Offering. Aankondiging • Jun 14
Restart Life Introduces Brain Qa -A Wholly Owned Brand Restart Life Sciences Corp. to introduce Brain Qa, a wholly owned brand developed by the Company. The first product under the Brain Qa brand will be the Brain Qa Healthy Cereal, which follows the product line established by the highly anticipated Brain Ballsa in cereal form. Brain Qa Healthy Cereal will be produced in collaboration with the Company's established co-packing partner in British Columbia. The Company will initiate its first production run when it strategically aligns with broader organizational objectives and the rollout of complementary in-house brands that support Restart Life's long-term vision. While product formulations, packaging, and regulatory elements are in advanced stages of preparation, finalization and submission for production will occur in due course. This product is positioned to strengthen the Company's growing portfolio of wellness-focused offerings and rein force its commitment to delivering innovative, high-im pact solutions in line with its strategic roadmap. The initial launch of Brain Qa Healthy Cereal will feature three distinct flavor variations with plans for future expansion to include additional flavors and product variations. The cereal will be available in sachets and travel-sized on-the-go packs, designed for maximum convenience, as well as wholesale options to accommodate a variety of consumer needs. In addition to the Brain Qa Healthy Cereal, the Company is actively working on developing a range of other products under the Brain Qa brand, aimed at further enhancing cognitive health, mental clarity, and overall well-being. These products will expand the BrainQa product line to address the evolving needs ofhealth-conscious consum ers and support Restart Life's broader m ission to deliver innovative wellness solutions. As part of this effort, Steve Loutskou, CEO of Restart Life Sciences, recently completed a tour ofthe co-packer's production facility. The visit focused on finalizing key arrangements for the production line, packaging, shipping, ingredient storage, and scaling production. This hands-on engagement underscores the Company's commitment to ensuring high-quality production and efficient logistics as it works to bring Brain Qa to market. The development of Brain Qa aligns with Restart Life's broader strategy to offer clean-label, and functionally beneficial products for health-conscious consumers. The Company remains committed to expanding its product offerings and driving sustained growth within the health and wellness sector. Restart Life expresses its appreciation for the ongoing support ofits shareholders and looks forward to the introduction of Brain Qa in the near future. Aankondiging • Jan 17
Restart Life Sciences Corp. announced that it expects to receive CAD 0.5 million in funding Restart Life Sciences Corp announced a private placement of 4,347,826 units at a price CAD 0.115 per unit for gross proceeds CAD 499,999.99 on January 15, 2025. Each unit consists of one common share and one transferable common warrant. The warrant will be exercisable to one share at exercise price CAD 0.15 per share for period of 12 months from the date of issuance. all securities are subjected to hold period of 4 months from date of issuance. Aankondiging • Dec 03
Restart Life Sciences Corp., Annual General Meeting, Feb 07, 2025 Restart Life Sciences Corp., Annual General Meeting, Feb 07, 2025. Location: vancouver Canada Aankondiging • Oct 24
Nova Mentis Life Science Corp Announces Chief Executive Officer Changes Nova Mentis Life Science Corp. announced the appointment of Steve Loutskou, Director of the Company, as Chief Executive Officer, effective October 22, 2024. This strategic initiative aimed at enhancing the company and positioning for future growth. With over 20 years of experience as a seasoned serial entrepreneur, Mr. Loutskou has built a remarkable career filled with numerous success stories. He excels in guiding early-stage startups through to mature commercialization, showcasing exceptional skills in navigating the complexities of financing. His extensive background in business management, operations, and financing spans various industry sectors. Mr. Loutskou originally co-founded Plant & Co formerly Cannvas Medtech, which has since evolved into Happy Belly Food Group. Happy Belly is a prominent consolidator of emerging food brands, with over 400 restaurants in the pipeline. As a trailblazer in innovative ventures, Mr. Loutskou's strategic vision and financial expertise have propelled startups to success while attracting investment. His ongoing influence is crucial in shaping the future of business through insightful strategies and proficient management. William Rascan has resigned from his roles as CEO of the Company. Mr. Rascan has been an integral part of the Company for over 12 years, playing a key role in its growth and milestones. Under his leadership, the Company underwent a significant transformation, transitioning from Weststar to Liberty Leaf Holdings, during which time the Company achieved a market capitalization exceeding $100 million. Additionally, Mr. Rascan guided the Company's evolution into Nova Mentis, becoming the first biotech firm to secure orphan drug designation for the use of psilocybin in treating Fragile X Syndrome (FXS) in both the United States and the European0 Union. The Company expresses its sincere gratitude to Mr. Rascan for his many years of dedicated service and wishes him continued success in his future endeavors. Aankondiging • Oct 23
Nova Mentis Life Science Corp. Announces Executive Changes Nova Mentis Life Science Corp. announced the appointment of Steve Loutskou, Director of the Company, as President, effective October 22, 2024. This strategic initiative aimed at enhancing the company and positioning for future growth. With over 20 years of experience as a seasoned serial entrepreneur, Mr. Loutskou has built a remarkable career filled with numerous success stories. He excels in guiding early-stage startups through to mature commercialization, showcasing exceptional skills in navigating the complexities of financing. His extensive background in business management, operations, and financing spans various industry sectors. Mr. Loutskou originally co-founded Plant & Co formerly Cannvas Medtech, which has since evolved into Happy Belly Food Group. Happy Belly is a prominent consolidator of emerging food brands, with over 400 restaurants in the pipeline. As a trailblazer in innovative ventures, Mr. Loutskou's strategic vision and financial expertise have propelled startups to success while attracting investment. His ongoing influence is crucial in shaping the future of business through insightful strategies and proficient management. William Rascan has resigned from his roles as President and Director of the Company. Mr. Rascan has been an integral part of the Company for over 12 years, playing a key role in its growth and milestones. Under his leadership, the Company underwent a significant transformation, transitioning from Weststar to Liberty Leaf Holdings, during which time the Company achieved a market capitalization exceeding $100 million. Additionally, Mr. Rascan guided the Company's evolution into Nova Mentis, becoming the first biotech firm to secure orphan drug designation for the use of psilocybin in treating Fragile X Syndrome (FXS) in both the United States and the European0 Union. The Company expresses its sincere gratitude to Mr. Rascan for his many years of dedicated service and wishes him continued success in his future endeavors. Aankondiging • Sep 25
Nova Mentis Life Science Corp., Annual General Meeting, Dec 03, 2024 Nova Mentis Life Science Corp., Annual General Meeting, Dec 03, 2024. Location: vancouver Canada Aankondiging • Dec 12
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director Nova Mentis Life Science Corp. announces the resignation of Dr. Stephen Glazer as Chief Scientific Officer and a Director of the Company, effective December 6, 2023. In consideration of the resignation received from Dr. Glazer, he will not stand for re-election at the Company's upcoming annual general meeting of shareholders on December 28, 2023. The Board would like to thank Dr. Glazer for his involvement with Nova and wishes him the best in future endeavors. Aankondiging • Oct 28
Nova Mentis Life Science Corp., Annual General Meeting, Dec 29, 2023 Nova Mentis Life Science Corp., Annual General Meeting, Dec 29, 2023. Aankondiging • Feb 16
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial Nova Mentis Life Science Corp. announced it has received an exemption under Section 56 of the Controlled Drugs and Substances Act allowing the Company to proceed with the first- ever Phase IIA clinical trial assessing repetitive, oral microdose psilocybin therapy for fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD). A Section 56 exemption enables an approved medical professional to prescribe select controlledsubstances without legal consequence, in order to better treat people with otherwise treatment-resistant conditions. KGK Science and NOVA have partnered to conduct a pioneering first clinical trial to investigate the effects of microdose psilocybin on the cognitive and behavioural symptoms associated with FXS. The results of the 10-person, open-label study will be used to support NOVA's drug development program under FDA Orphan Drug designation, which was received in late 2021. The trial will be led by KGK Science and recruiting efforts are expected to begin in late First Quarter 2023. The clinical trial received a No Objection Letter from Health Canada in December of 2022 and is one of the first approved studies that will permit participants to take home the drug for dosing every other day. Nova Mentis has completed production of pharmaceutical grade cGMP synthetic psilocybin 1.5 mg microdose capsules that will be used to advance the necessary research and development steps needed for successful drug regulatory approval and future commercialization. Aankondiging • Jan 19
Nova Mentis Life Science Corp. Announces Board Changes Nova Mentis Life Science Corp. announced the appointment of Derek Ivany to the position of Executive Chairman. In this new role, Mr. Ivany's mandate will include specific focus on corporate development outreach, mergers and acquisitions, capital markets support and other strategic value enhancement initiatives. Mr. Ivany has been a long-term shareholder and supporter of NOVA by virtue of his previous position as founder, President and Director of Pilz Bioscience Corp., a company that he started with NOVA's Dr. Marvin S. Hausman that was subsequently acquired by NOVA in November 2020. His initial interest in autism spectrum disorder (ASD) research was sparked by a personal connection to the disorder. Derek's brother, who was diagnosed with ASD at a young age, registers at the upper end of the ASD scale and is largely non-verbal. Derek has witnessed first-hand the devastating effects that severe autism can have on a family and is passionate about doing his part to advance research in this area. Mr. Ivany has a rich history of successfully working with publicly traded companies and helping generate significant shareholder value in a variety of diverse industry segments. Having worked with many international groups, Mr. Ivany has established a network of high-profile contacts across such sectors as medicinal products, health and wellness, mining, oil and gas, coffee, technology, horse racing and real estate. In order to accommodate the new director appointment, Steve Feldman has resigned from the NOVA's Board of Directors.